Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Biomarkers of metabolism disorders and treatment use according to CKD progression status. Baseline characteristics | Improvers(n = 62) | Non improvers(n = 332) | p-value: 25(OH)D (ng/mL) | 26.0 [15.7 to 32.9] | 18.5 [11.0 to 28.4] | 0.004

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Between January 2000 and January 2008, 1269 patients were included after providing informed consent.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Renal Function Can Improve at Any Stage of Chronic Kidney Disease

Study design awaiting verification · PLoS ONE · 2013

Original publication title

Renal Function Can Improve at Any Stage of Chronic Kidney Disease

Lise Weis; Marie Metzger; Jean-Philippe Haymann; Eric Thervet; Martin Flamant; François Vrtovsnik; Cédric Gauci; Pascal Houillier; Marc Froissart; Emmanuel Letavernier; Bénédicte Stengel; Jean-Jacques Boffa; on behalf of the NephroTest Study Group

© 2013 Weis et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

GFR improvement is possible in CKD patients at any CKD stage through stage 4 to 5. It is noteworthy that this GFR improvement is associated with a decrease in the number of metabolic complications over time.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Even though renal function decline is considered relentless in chronic kidney disease (CKD), improvement has been shown in patients with hypertensive nephropathy. Whether this can occur in any type of nephropathy and at any stage is unknown as are the features of patients who improve.

Source: Introduction

Abstract: What methods does the paper describe?

We identified 406 patients in the NephroTest cohort with glomerular filtration rates (mGFR) measured by 51Cr-EDTA clearance at least 3 times during at least 2 years of follow-up. Individual examination of mGFR trajectories by 4 independent nephrologists classified patients as improvers, defined as those showing a sustained mGFR increase, or nonimprovers. Twelve patients with erratic trajectories were excluded. Baseline data were compared between improvers and nonimprovers, as was the number of recommended therapeutic targets achieved over time (specifically, for systolic and diastolic blood pressure, proteinuria, and use of renin angiotensin system blockers).

Source: Methods

Abstract: Results

Measured GFR improved over time in 62 patients (15.3%). Their median mGFR slope was +1.88[IQR 1.38, 3.55] ml/min/year; it was −2.23[−3.9, −0.91] for the 332 nonimprovers. Improvers had various nephropathies, but not diabetic glomerulopathy or polycystic kidney disease. They did not differ from nonimprovers for age, sex, cardiovascular history, or CKD stage, but their urinary albumin excretion rate was lower. Improvers achieved significantly more recommended therapeutic targets (2.74±0.87) than nonimprovers (2.44±0.80, p<0.01). They also had fewer CKD-related metabolic complications and a lower prevalence of 25OH-vitamin-D deficiency.

Source: Results

Abstract: Conclusion

GFR improvement is possible in CKD patients at any CKD stage through stage 4 to 5. It is noteworthy that this GFR improvement is associated with a decrease in the number of metabolic complications over time.

Source: Conclusion
Authors’ abstract

Introduction

Even though renal function decline is considered relentless in chronic kidney disease (CKD), improvement has been shown in patients with hypertensive nephropathy. Whether this can occur in any type of nephropathy and at any stage is unknown as are the features of patients who improve.

Methods

We identified 406 patients in the NephroTest cohort with glomerular filtration rates (mGFR) measured by 51Cr-EDTA clearance at least 3 times during at least 2 years of follow-up. Individual examination of mGFR trajectories by 4 independent nephrologists classified patients as improvers, defined as those showing a sustained mGFR increase, or nonimprovers. Twelve patients with erratic trajectories were excluded. Baseline data were compared between improvers and nonimprovers, as was the number of recommended therapeutic targets achieved over time (specifically, for systolic and diastolic blood pressure, proteinuria, and use of renin angiotensin system blockers).

Results

Measured GFR improved over time in 62 patients (15.3%). Their median mGFR slope was +1.88[IQR 1.38, 3.55] ml/min/year; it was −2.23[−3.9, −0.91] for the 332 nonimprovers. Improvers had various nephropathies, but not diabetic glomerulopathy or polycystic kidney disease. They did not differ from nonimprovers for age, sex, cardiovascular history, or CKD stage, but their urinary albumin excretion rate was lower. Improvers achieved significantly more recommended therapeutic targets (2.74±0.87) than nonimprovers (2.44±0.80, p<0.01). They also had fewer CKD-related metabolic complications and a lower prevalence of 25OH-vitamin-D deficiency.

Conclusion

GFR improvement is possible in CKD patients at any CKD stage through stage 4 to 5. It is noteworthy that this GFR improvement is associated with a decrease in the number of metabolic complications over time.

Publication and source details

Original title: Renal Function Can Improve at Any Stage of Chronic Kidney Disease

Lise Weis; Marie Metzger; Jean-Philippe Haymann; Eric Thervet; Martin Flamant; François Vrtovsnik; Cédric Gauci; Pascal Houillier; Marc Froissart; Emmanuel Letavernier; Bénédicte Stengel; Jean-Jacques Boffa; on behalf of the NephroTest Study Group

PLoS ONE · 2013

¶ Membership of the NephroTest Study Group is provided in the Acknowledgments.

* E-mail: jean-jacques.boffa@tnn.aphp.fr

Competing Interests: Marc Froisart has received consulting or lecture fees or research funds from Affymax, Genzyme, Hoffmann-La Roche, Novartis, Sandoz, Shire, Takeda, and Vifor International. Marc Froisart has been employed by Amgen since January 1, 2011, but was a full-time academic associate professor during the time of study conception and data collection. Bénédicte Stengel has received research funds from Amgen, Baxter, Genzyme (Sanofi), Fresenius, MSD, and GSK. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Conceived and designed the experiments: LW JJB. Analyzed the data: LW MM JPH ET M. Flamant FV CG PH M. Froissart EL BS JJB. Wrote the paper: LW MM JPH ET M. Flamant FV CG PH M. Froissart EL BS JJB. Acquired the data: M. Flamant JPH PH M. Froissart MM BS. Drafted, revised and approved the manuscript: LW MM JPH ET M. Flamant FV CG PH M. Froissart EL BS JJB.

© 2013 Weis et al2013Weis et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.The NephroTest CKD cohort study is supported by grants from: Inserm GIS-IReSP AO 8113LS TGIR (BS); French Ministry of Health AOM 09114 (MF); Inserm AO 8022LS (BS); Agence de la Biomédecine R0 8156LL (BS); AURA (MFr) and Roche 2009-152-447G (MFr). The Nephrotest initiative was also sponsored by unrestricted grants from F. Hoffman-La Roche Ltd. (LM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T12:21:16.333465+00:00

DOI: 10.1371/journal.pone.0081835 · PMC3862566